Dong, X., Huang, J., Cao, R., & Liu, L. (2010). Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. Medical Oncology, 28, 1425–1429.
To verify the activity and safety of palonosetron in patients with non-small cell lung cancer treated with chemotherapy
Patients were randomized to either a single dose of 0.25 mg IV bolus palonosetron or 8 mg IV ondansetron on day one. Only dexamethasone was permitted as rescue medication. Doctors recorded daily episodes of vomiting and nausea and use of rescue medication. Patients were followed for seven days.
The study was conducted at a single site in China.
All patients were in active treatment.
This was a randomized, controlled study.
The following measurement were used.
Palonosetron could be an effective and safe drug for the prevention of CINV associated with HEC. Palonosetron may be particularly helpful in prevention of CINV in the delayed period.
In countries where aprepitant is not widely available, palonosetron could be an option for 5-HT3 receptor antagonists for CINV with HEC among patients with non-small cell lung cancer.